<ul> <li> Secarna's LNAplus™ ASOs suppress expression of NLRP3, a central component of the inflammasome pathway, which is overactive in many inflammatory diseases </li> <li> Cryopyrin-associated periodic syndrome (CAPS) is a group of rare inherited autoinflammatory diseases driven by overactive NLRP3, resulting in systemic inflammation </li> <li> With NLRP3-specific ASOs, inflammatory downstream effects were interrupted in immune cells and strong symptom relief and significant prolongation of survival was achieved in a CAPS disease model.</li></ul>